Syncytia formation by SARS‐CoV‐2‐infected cellsJulian Buchrieser, Olivier Schwartz|The EMBO Journal|2020Cited by 497
Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfectionFloriane Gallais, Samira Fafi‐Kremer, Yves Hansmann et al.|EBioMedicine|2021Cited by 239
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasionDelphine Planas, Olivier Schwartz|Nature Communications|2024Cited by 237
Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2Tia A. Tummino, Brian K. Shoichet, Veronica V. Rezelj et al.|Science|2021Cited by 223
Sex Differences in the Evolution of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2Ludivine Grzelak, Samira Fafi‐Kremer, Aurélie Velay et al.|The Journal of Infectious Diseases|2021Cited by 85